Return to homepagePandemic Pact

Assessing the role of clonal hematopoiesis in respiratory infection risk and vaccine responses in the elderly

Grant number: PSI_vlasschaert_c_rauh_m_assessing_the_role_of_clonal_hematopoiesis_in_respiratory_infection_risk_and_vaccine_responses_in_the_elderly_q4_2024

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2024
    2026

  • Known Financial Commitments (USD)

    $22,192.71

  • Principal Investigator

    C Vlasschaert

  • Research Location

    Canada

  • Lead Research Institution

    Queen's University

  • Research Priority Alignment

    N/A

  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Clinical trials for disease management

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Older adults (65 and older)

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Clonal hematopoiesis of indeterminate potential (CHIP) is a condition that emerges as we age, affecting around 10% of those over 65. In CHIP, a significant portion of an individual's blood cells are produced from a single, abnormal stem cell, which has been linked to an increased risk of several chronic illnesses, including heart and lung diseases. This research project aims to explore whether CHIP also makes older adults more susceptible to respiratory infections, such as the flu or COVID-19, and how it might influence their response to vaccinations. Understanding CHIP's role in infection risk could lead to better management strategies, including targeted vaccination strategies and new treatments that address the underlying genetic changes in CHIP. This could be particularly beneficial for aging populations, helping them lead healthier lives with fewer hospital visits.